Predictive low-glucose suspend system and glycemic variability.

Introduction: Predictive low-glucose suspend (PLGS) system helps prevent hypoglycemia. Aim: To evaluate the effect of PLGS therapy on GV and percentage of time in range (TIR), time below range (TBR), and time above range (TAR) in pediatric type 1 diabetic patients. Method: HbA_1c, coefficient of variation (CV), standard deviation (SD), and percentage of TIR, TBR, and TAR were evaluated in type 1 diabetic (T1D) pediatric patients followed up between Jan 2016 and Mar 2020 using PLGS system. Results: Mean ages of diagnosis and duration of diabetes were 6.7 ± 4.1 and 8.2 ± 4.3 years, respectively. Nineteen of the patients were male (46.3%) and 22 were female (53.7%). Twenty-two (53.7%) of the patients were using low-glucose suspend system and 19 (46.3%) were on multiple daily injection therapy (MDI). On PLGS therapy, the 3rd, 6th, 9th, and 12th months' HbA_1c of patients were not different from previous years' mean HbA_1c in all participants. In the 3rd, 6th, 9th, and 12th months of PLGS therapy, % of TIR were 65.34 ± 14.75%, 65.80 ± 14.67%, 66.58 ± 11.21%, and 70.04 ± 10.16%, respectively (p = 0.01). Although statistically insignificant, CV decreased from 36.33 to 34.30% and SD decreased from 60.14 to 58.60 in the 1-year follow-up period (p = 0.062 and p = 0.246). Conclusion: With PLGS therapy, TIR was > 70% and the time spent in hypoglycemia was very low. [ABSTRACT FROM AUTHOR]